ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Everest Medicines Ltd. ?
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
- Poor long term growth as Operating profit has grown by an annual rate 13.29% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -217.30
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -7.16%, its profits have risen by 14.8%
3
Underperformed the market in the last 1 year
- Even though the market (Hang Seng Hong Kong) has generated returns of 26.67% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -7.16% returns
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Everest Medicines Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Everest Medicines Ltd.
-7.26%
1.68
68.69%
Hang Seng Hong Kong
27.36%
1.03
25.88%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
783.99%
EBIT Growth (5y)
13.29%
EBIT to Interest (avg)
-217.30
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.26
Sales to Capital Employed (avg)
0.06
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.79
EV to EBIT
-23.77
EV to EBITDA
-28.83
EV to Capital Employed
6.12
EV to Sales
25.61
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-25.75%
ROE (Latest)
-17.20%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend
Not enough Data to analyse Financial Trend
Not enough Data to analyse Financial Trend
Here's what is working for Everest Medicines Ltd.
Net Sales
At HKD 439.52 MM has Grown at 247.62%
Year on Year (YoY)MOJO Watch
Near term sales trend is extremely positive
Net Sales (HKD MM)
Net Profit
Higher at HKD -440.97 MM
than preceding 12 month period ended Dec 2024MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (HKD MM)
Inventory Turnover Ratio
Highest at 12.08% and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Net Sales
Highest at HKD 439.52 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (HKD MM)
Debtors Turnover Ratio
Highest at 2.74%
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -142.27% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at HKD 85.93 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (HKD MM)
Depreciation
At HKD 85.93 MM has Grown at 45.75%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (HKD MM)
Here's what is not working for Everest Medicines Ltd.
Interest
At HKD 12.38 MM has Grown at 44.16%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (HKD MM)
Cash and Eqv
Lowest at HKD 1,706.26 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at -25.25 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
